Evidence map›Paper›PMID 35457347›Full record

ArticleInternational journal of environmental research and public health2022

Influence of

Małgorzata Śmiarowska, Bogusław Brzuchalski, Elżbieta Grzywacz, Damian Malinowski, Anna Machoy-Mokrzyńska, Anna Pierzchlińska, Monika Białecka

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Interaction BetweenNeurology international · 2025
    Article
  3. Role of Nanomedicine in Transforming Pharmacotherapy for Substance Use Disorder (SUD).Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Małgorzata ŚmiarowskaDepartment of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, Aleja Powstancόw Wielkopolskich 72 St., 70-111 Szczecin, Poland.
Bogusław BrzuchalskiDepartment of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, Aleja Powstancόw Wielkopolskich 72 St., 70-111 Szczecin, Poland.
Elżbieta GrzywaczDepartment of Experimental and Clinical Pharmacology, Pomeranian Medical University, Aleja Powstancόw Wielkopolskich 72 St., 70-111 Szczecin, Poland.
Damian MalinowskiDepartment of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, Aleja Powstancόw Wielkopolskich 72 St., 70-111 Szczecin, Poland.ORCID 0000-0001-8393-9627
Anna Machoy-MokrzyńskaDepartment of Experimental and Clinical Pharmacology, Pomeranian Medical University, Aleja Powstancόw Wielkopolskich 72 St., 70-111 Szczecin, Poland.
Anna PierzchlińskaDepartment of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, Aleja Powstancόw Wielkopolskich 72 St., 70-111 Szczecin, Poland.ORCID 0000-0002-1606-7918
Monika BiałeckaDepartment of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, Aleja Powstancόw Wielkopolskich 72 St., 70-111 Szczecin, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fetal alcohol spectrum disorders (FASD) in a course of high prenatal alcohol exposure (hPAE) are among the most common causes of developmental disorders. The main reason for pharmacological treatment of FASD children is attention deficit hyperactivity disorder (ADHD), and methylphenidate (MPH) is the drug of choice. The aim of the study was to assess whether children born of hPAE with ADHD, with or without morphological FASD, differ in terms of catechol-O-methyltransferase (

Indexed as

Attention Deficit Disorder with HyperactivityFetal Alcohol Spectrum DisordersMethylphenidatePrenatal Exposure Delayed EffectsCatechol O-MethyltransferaseChildFemaleGenotypeHumansPolymorphism, GeneticPregnancyReceptors, Dopamine D2Catechol O-MethyltransferaseCOMT protein, humanDRD2 protein, humanMethylphenidateReceptors, Dopamine D2attention deficit hyperactivity disorders (ADHD)catechol-O-methyltransferase (COMT)dopamine-2 receptor (DRD2)fetal alcohol spectrum disorders (FASD)gene polymorphismsmethylphenidate treatment

Identifiers

PMID35457347
PMCPMC9031832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.